Physician profile
David P Lerner
NPI 1831489418
$2,709.80
in general payments reported to CMS, 2019-2025
20 companies · $758 in 2025
The $758 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.61 · 2023: $836 · 2024: $1,101 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,694.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $612.23 | 2022-2024 | Briviact |
| Sk Life Science, INC. | $531.78 | 2023-2025 | Xcopri |
| Pfizer INC. | $270.34 | 2023-2025 | |
| Octapharma USA, INC. | $199.17 | 2023-2025 | Balfaxar, Panzyga, Fibryga |
| Eisai INC. | $175.81 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $164.02 | 2024-2025 | Ingrezza |
| Argenx US, INC. | $104.37 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Astrazeneca Pharmaceuticals LP | $96.84 | 2023-2024 | Andexxa |
| Alnylam Pharmaceuticals INC. | $94.33 | 2023-2024 | Amvuttra, Onpattro |
| Alexion Pharmaceuticals, INC. | $86.09 | 2024-2025 | Ultomiris |
| Biogen, INC. | $75.93 | 2025 | Vumerity, Tysabri, Leqembi |
| Neurelis, INC. | $53.33 | 2023 | Valtoco |
| Otsuka America Pharmaceutical, INC. | $49.72 | 2023 | Nuedexta, Rexulti |
| Janssen Biotech, INC. | $42.45 | 2025 | |
| Janssen Pharmaceuticals, INC | $38.69 | 2023 | Xarelto |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ceribell, INC. | $33.78 | 2025 | Pocket Eeg Device |
| Invivyd INC | $30.09 | 2025 | Pemgarda |
| Abbott Laboratories | $20.49 | 2025 | Infinity |
| Chiesi USA, INC. | $17.24 | 2023 | Cleviprex |
| Grifols USA, LLC | $13.10 | 2024 | Gamunex-C |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.